The MONALEESA-7 study showed that median progression free survival (PFS) for premenopausal women with ER/PR positive, HER2-normal, advanced breast cancer receiving similar cyclin-dependent kinase 4/6 (CDK4/6) inhibitor therapy is ~23 months, much longer than the 10 months seen in this case40. This evidence concerns the gene ERBB2 and breast carcinoma.